ACM
ALDR

Apex Capital Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Apex Capital Management’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		$3.02M Buy
123,227
+20,548
+20% +$476K 0.07% 179
2015
Q4 		$3.39M Buy
102,679
+7,266
+8% +$246K 0.08% 171
2015
Q3 		$3.13M Buy
+95,413
New +$4.06M 0.07% 173

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Apex Capital Management's ALDR Position: Q1 2016 in Review

Apex Capital Management increased its Alder Biopharmaceuticals (ALDR) stake by 20% in Q1 2016, buying an estimated $476K and bringing the position to 123,227 shares worth $3.02M. The position accounts for 0.07% of the portfolio, ranked #179.

Apex Capital Management first reported a position in ALDR in Q3 2015 and has held it in 3 quarters since. The position peaked at $3.39M in Q4 2015. 117 funds tracked by Wall St. Rank hold ALDR as of Q1 2016.

  • Apex Capital Management held 123,227 shares of Alder Biopharmaceuticals worth $3.02M as of Q1 2016.
  • Apex Capital Management bought 20,548 Alder Biopharmaceuticals shares in Q1 2016, an estimated $476K.
  • Alder Biopharmaceuticals made up 0.07% of Apex Capital Management's portfolio in Q1 2016, its #179 holding.
  • Apex Capital Management first reported a position in Alder Biopharmaceuticals in Q3 2015 and has held it in 3 quarters since.
  • Apex Capital Management's Alder Biopharmaceuticals position peaked at $3.39M in Q4 2015.
  • 117 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.